Dr Mark Dickson talks to ecancer at ASCO 2026 about findings from a phase III trial evaluating abemaciclib in patients with recurrent dedifferentiated liposarcoma.

Reviewing the study design, efficacy outcomes including progression-free survival, and the safety profile observed in the trial, he notes the potential clinical implications for management of this rare soft tissue sarcoma.